SC&H Capital Acts as Placement Agent for Capricor Therapeutics, Inc. (NASDAQ: CAPR)

Press Releases
Updated on: March 29, 2024

Capricor Therapeutics Announces $4 Million Registered Direct Offering

SC&H Capital, an investment banking and advisory firm focused on middle market and growth companies, announced that it acted as the placement agent for Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its recent $4 million registered direct offering.

Capricor entered into a Subscription Agreement with certain investors for the purchase and sale of 1,692,151 shares of common stock at a price of $2.40 per share and warrants to purchase up to 846,073 shares of common stock with an exercise price of $4.50 per share. The warrants will be exercisable six months and one day from the date of the closing of the offering and have a term of three years.

Capricor is a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics. The company’s lead programs target post myocardial infarction (heart attack), heart failure, and Duchenne muscular dystrophy.

Click here to read the official press release from Capricor.

Related Insights


Subscribe to our Insights

A collection of insights about our capabilities, solutions, people, and client successes.